Table 4.
Clinical trials on oncolytic virotherapy for high-grade gliomas.
| # | ClinicalTrials.gov Identifier | Title | Status | Phase | Diseases | # of Pts. Enrolled | Treatment | Locations |
|---|---|---|---|---|---|---|---|---|
| 1 | NCT00028158 | Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients with Recurrent Brain Cancer | Completed | I/II | Glioma Astrocytoma Glioblastoma |
65 | Drug: G207, an oncolytic virus | NA |
| 2 | NCT00157703 | G207 Followed by Radiation Therapy in Malignant Glioma | Completed | I | Malignant Glioma | 9 | Drug: G207, an oncolytic virus | USA |
| 3 | NCT02031965 | Oncolytic HSV-1716 in Treating Younger Patients with Refractory or Recurrent High-Grade Glioma That Can Be Removed by Surgery | Terminated | I | Brain and Central Nervous System Tumors | 2 | Biological: oncolytic HSV-1716; Drug: dexamethasone Procedure: therapeutic conventional surgery |
USA |
| 4 | NCT03152318 | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5 v.2 | Recruiting | I | Brain and Central Nervous System Tumors |
108 | Drug: rQNestin, Cyclophosphamide; Procedure: Stereotactic biopsy | USA |
| 5 | NCT02197169 | DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors | Completed | I | Glioblastoma Gliosarcoma |
37 | Single intratumoral injection of DNX-2401; Drug: Interferon-gamma | USA |
| 6 | NCT01174537 | New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma | Withdrawn | I/II | Glioblastoma Sarcoma Neuroblastoma |
0 | Biological: New Castle Disease Virus | IL |
| 7 | NCT00390299 | Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme | Completed | I | Anaplastic Astrocytoma Anaplastic Oligodendroglioma Mixed Glioma Recurrent Glioblastoma |
23 | Biological: Carcinoembryonic Antigen-Expressing Measles Virus; Therapeutic Conventional Surgery | USA |
| 8 | NCT01301430 | Parvovirus H-1 (ParvOryx) in Patients with Progressive Primary or Recurrent Glioblastoma Multiforme. |
Completed | I/II | Glioblastoma Multiforme | 18 | Drug: H-1PV | DE |
| 9 | NCT01582516 | Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients with Recurrent Glioblastoma | Completed | I/II | Brain Tumor Recurring Glioblastoma |
20 | Biological: delta-24-RGD adenovirus | NL |
| 10 | NCT02062827 | Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma | Recruiting | I | Recurrent Glioblastoma Multiforme Progressive Glioblastoma Multiforme Anaplastic Astrocytoma or Gliosarcoma |
36 | Biological: M032 (NSC 733972) | USA |
| 11 | NCT03911388 | HSV G207 in Children with Recurrent or Refractory Cerebellar Brain Tumors | Recruiting | I | Brain and Central Nervous System Tumors | 15 | Biological: G207 | USA |
| 12 | NCT00805376 | DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas | Completed | I | Brain Cancer Central Nervous System Diseases |
37 | Drug: DNX-2401 Procedure: Tumor Removal |
USA |
| 13 | NCT03896568 | Oncolytic Adenovirus DNX-2401 in Treating Patients with Recurrent High-Grade Glioma | Recruiting | I | Brain and Central Nervous System Tumors | 36 | Oncolytic Adenovirus Ad5-DNX-2401 Therapeutic Conventional Surgery |
USA |
| 14 | NCT01956734 | Virus DNX2401 and Temozolomide in Recurrent Glioblastoma | Completed | I | Glioblastoma Multiforme Recurrent Tumor |
31 | Procedure: DNX2401 and Temozolomide | ES |
| 15 | NCT02986178 | PVSRIPO in Recurrent Malignant Glioma | Active, not recruiting |
II | Malignant Glioma | 122 | PVSRIPO | USA |
| 16 | NCT03973879 | Combination of PVSRIPO and Atezolizumab for Adults with Recurrent Malignant Glioma | Withdrawn | I/II | Malignant Glioma | 0 | Biological: PVSRIPO Drug: Atezolizumab |
NA |
| 17 | NCT03043391 | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children | Recruiting | I | Brain and Central Nervous System Tumors | 12 | Biological: Polio/Rhinovirus Recombinant (PVSRIPO) | USA |
| 18 | NCT01491893 | PVSRIPO for Recurrent Glioblastoma (GBM) | Active, not recruiting |
I | Glioma Malignant Glioma | 61 | Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO) |
USA |
| 19 | NCT03072134 | Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma | Active, not recruiting |
I | Brain and Central Nervous System Tumors | NA | Neural stem cells loaded with an oncolytic adenovirus |
NA |
| 20 | NCT03657576 | Trial of C134 in Patients with Recurrent GBM | Active, not recruiting |
I | Glioblastoma Multiforme of Brain Anaplastic Astrocytoma of Brain Gliosarcoma of Brain |
24 | Biological: C134 | USA |
| 21 | NCT02798406 | Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects | Active, not recruiting |
II | Brain and Central Nervous System Tumors | 49 | Biological: DNX-2401 Biological: pembrolizumab | USA |
| 22 | NCT03714334 | DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma | Recruiting | I | Glioblastoma Glioblastoma, Adult |
24 | Drug: DNX-2440 injection | ES |
| 23 | NCT03294486 | Safety and Efficacy of the Oncolytic Virus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients | Recruiting | I/II | Glioblastoma Brain Cancer |
78 | Drug: Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®) | FR |
| 24 | NCT02457845 | HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors |
Active, not recruiting |
I | Brain and Central Nervous System Tumors | 12 | Biological: G207 | USA |
| 25 | NCT00006106 | ONYX-015 With Cisplatin and Fluorouracil in Treating Patients with Advanced Head and Neck Cancer | Withdrawn | I | Lip and Oral Cavity Cancer Head and Neck Cancer Oropharyngeal Cancer |
0 | Drug: Cisplatin, Fluorouracil Drug: ONYX-015 |
USA |
| 26 | NCT00528684 | Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas | Completed | I | Malignant Glioma | 18 | Biological: REOLYSIN® |
USA |
DE: Germany; ES: Spain; FR: France; GBM: Glioblastoma Multiforme; HSV: Herpes Simplex Virus; IL: Israel; IFN-γ: Interferon Gamma; NDV: New Castle Disease Virus; NL: Netherlands; Pts: Patients; PVSRIPO: Recombinant Nonpathogenic Poliorhinovirus; USA: United States of America.